---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086034"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T18:26:02.712577+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment

## Summary
- Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).
- Achieved commercial sales milestone under RIFA with HealthCare Royalty, eligible for final $25M tranche.
- Over 125 new BBS prescriptions in Q2 2023; >425 since FDA approval in June 2022.
- Phase 3 hypothalamic obesity trial enrollment expected by Q4 2023; IND for RM-718 by end of 2023.
- Cash, cash equivalents and short-term investments $253.6M as of June 30, 2023.

## SEC filing metadata
- accession: 0001104659-23-086034
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/0001104659-23-086034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/tm2322430d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086034
- JSON: https://secwatch.observer/filing/0001104659-23-086034.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086034.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $19.2 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $19.2 million
  - Result: reported results
  source text: Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/0001104659-23-086034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.